{
  "id": 169149,
  "title": "Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial",
  "url": "https://urgent.news/2026/08/05/dronabinol-for-nightmares-in-post-traumatic-stress-disorder-a",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-05T00:00:00.000Z",
  "source": {
    "name": "Nature Medicine",
    "slug": "nature-medicine",
    "url": "https://www.nature.com/articles/s41591-026-04546-9"
  },
  "original_language": "en",
  "account": "A recent randomized controlled trial investigated the potential of dronabinol, a synthetic form of tetrahydrocannabinol (THC), in alleviating nightmares among individuals suffering from post-traumatic stress disorder (PTSD). The study, conducted across multiple centers and involving 171 patients, found that those receiving dronabinol experienced a more significant reduction in nightmare frequency and intensity compared to those receiving a placebo.\n\nThe primary outcome of the trial, measured using the Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) B2 item, indicated that the dronabinol group demonstrated a statistically significant improvement (−1.50) compared to the placebo group (P < 0.001). While adverse events were reported in both groups, they were more frequent among those taking dronabinol (78 out of 87, 89.7%), with five patients experiencing treatment discontinuation due to adverse effects.\n\nDespite these findings, the trial acknowledges the need for further investigation into the long-term efficacy and safety of dronabinol in treating PTSD-related nightmares.",
  "summary": "Nature Medicine, Published online: 05 August 2026; doi:10.1038/s41591-026-04546-9 A randomized controlled trial found that dronabinol significantly reduced both the frequency and intensity of nightmares in patients with PTSD over 10 weeks, compared with placebo.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}